A Replicating Cytomegalovirus-Based Vaccine Encoding a Single Ebola Virus Nucleoprotein CTL Epitope Confers Protection against Ebola Virus
dc.contributor.author | Tsuda, Y | |
dc.contributor.author | Caposio, P | |
dc.contributor.author | Parkins, CJ | |
dc.contributor.author | Botto, S | |
dc.contributor.author | Messaoudi, I | |
dc.contributor.author | Cicin-Sain, L | |
dc.contributor.author | Feldmann, H | |
dc.contributor.author | Jarvis, Michael A | |
dc.date.accessioned | 2015-07-17T07:59:38Z | |
dc.date.available | 2015-07-17T07:59:38Z | |
dc.date.issued | 2011 | |
dc.identifier.issn | 1935-2727 | |
dc.identifier.issn | 1935-2735 | |
dc.identifier.other | e1275 | |
dc.identifier.uri | http://hdl.handle.net/10026.1/3436 | |
dc.description | Times Cited: 8 | |
dc.description.abstract |
BACKGROUND: Human outbreaks of Ebola virus (EBOV) are a serious human health concern in Central Africa. Great apes (gorillas/chimpanzees) are an important source of EBOV transmission to humans due to increased hunting of wildlife including the 'bush-meat' trade. Cytomegalovirus (CMV) is an highly immunogenic virus that has shown recent utility as a vaccine platform. CMV-based vaccines also have the unique potential to re-infect and disseminate through target populations regardless of prior CMV immunity, which may be ideal for achieving high vaccine coverage in inaccessible populations such as great apes. METHODOLOGY/PRINCIPAL FINDINGS: We hypothesize that a vaccine strategy using CMV-based vectors expressing EBOV antigens may be ideally suited for use in inaccessible wildlife populations. To establish a 'proof-of-concept' for CMV-based vaccines against EBOV, we constructed a mouse CMV (MCMV) vector expressing a CD8+ T cell epitope from the nucleoprotein (NP) of Zaire ebolavirus (ZEBOV) (MCMV/ZEBOV-NP(CTL)). MCMV/ZEBOV-NP(CTL) induced high levels of long-lasting (>8 months) CD8+ T cells against ZEBOV NP in mice. Importantly, all vaccinated animals were protected against lethal ZEBOV challenge. Low levels of anti-ZEBOV antibodies were only sporadically detected in vaccinated animals prior to ZEBOV challenge suggesting a role, at least in part, for T cells in protection. CONCLUSIONS/SIGNIFICANCE: This study demonstrates the ability of a CMV-based vaccine approach to protect against an highly virulent human pathogen, and supports the potential for 'disseminating' CMV-based EBOV vaccines to prevent EBOV transmission in wildlife populations. | |
dc.format.extent | e1275-e1275 | |
dc.format.medium | 8 | |
dc.language | en | |
dc.language.iso | en | |
dc.publisher | Public Library of Science (PLoS) | |
dc.subject | Animals | |
dc.subject | CD8-Positive T-Lymphocytes | |
dc.subject | Drug Carriers | |
dc.subject | Ebola Vaccines | |
dc.subject | Ebolavirus | |
dc.subject | Epitopes, T-Lymphocyte | |
dc.subject | Female | |
dc.subject | Genetic Vectors | |
dc.subject | Hemorrhagic Fever, Ebola | |
dc.subject | Mice | |
dc.subject | Mice, Inbred C57BL | |
dc.subject | Muromegalovirus | |
dc.subject | Nucleoproteins | |
dc.subject | T-Lymphocytes, Cytotoxic | |
dc.subject | Vaccines, Subunit | |
dc.subject | Vaccines, Synthetic | |
dc.title | A Replicating Cytomegalovirus-Based Vaccine Encoding a Single Ebola Virus Nucleoprotein CTL Epitope Confers Protection against Ebola Virus | |
dc.type | journal-article | |
dc.type | Article | |
plymouth.author-url | https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000294479800029&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008 | |
plymouth.issue | 8 | |
plymouth.volume | 5 | |
plymouth.publication-status | Published online | |
plymouth.journal | Plos Neglected Tropical Diseases | |
dc.identifier.doi | 10.1371/journal.pntd.0001275 | |
plymouth.organisational-group | /Plymouth | |
plymouth.organisational-group | /Plymouth/Faculty of Health | |
plymouth.organisational-group | /Plymouth/Faculty of Health/School of Biomedical Sciences | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine | |
plymouth.organisational-group | /Plymouth/Research Groups | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED) | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CBR | |
plymouth.organisational-group | /Plymouth/Users by role | |
plymouth.organisational-group | /Plymouth/Users by role/Academics | |
dc.publisher.place | United States | |
dcterms.dateAccepted | 2011-06-29 | |
dc.identifier.eissn | 1935-2735 | |
dc.rights.embargoperiod | Not known | |
rioxxterms.versionofrecord | 10.1371/journal.pntd.0001275 | |
rioxxterms.licenseref.uri | http://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.type | Journal Article/Review |